Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
Rhea-AI Summary
Spero Therapeutics (NASDAQ: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, will release its first quarter 2025 financial results after market close on Tuesday, May 13, 2025. The company will also provide a business update but has stated it will not host a conference call for this earnings announcement.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When will Spero Therapeutics (SPRO) release Q1 2025 earnings?
Will Spero Therapeutics hold an earnings call for Q1 2025 results?
What is Spero Therapeutics' (SPRO) main business focus?
What stock exchange is Spero Therapeutics listed on?
